The overexpression or amplification of FGFR1 has been reported in 10–20% of breast cancer, head and neck squamous cell carcinoma, and lung squamous cell carcinoma, and its association with poor survival has been reported in breast cancer, head and neck squamous cell carcinoma, but not in lung cancer [14–16]. Here, FGFR1 is linked to squamous cell lung carcinoma.